Congratulations @jcstark.bsky.social and the team, antibody-lectin chimeras (AbLecs), a new modality for cancer immune therapy, now published @natbiotech.nature.com. These bispecifics can block glyco-immune checkpoint receptor ligands directly at the immune synapse/activate immune effector functions
Antibody-lectin chimeras for glyco-immune checkpoint blockade - @jcstark.bsky.social @carolynbertozzi.bskyverified.social go.nature.com/4aRDpk8